Picture loading failed.

Pre-Made Erenumab biosimilar, Whole mAb, Anti-CALCRL/CGRPR Antibody: Anti-CRLR/LMPHM8 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Erenumab, sold under the brand name Aimovig, is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-193-1mg 1mg 3090
GMP-Bios-ab-193-10mg 10mg Inquiry
GMP-Bios-ab-193-100mg 100mg Inquiry
GMP-Bios-ab-193-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Erenumab biosimilar, Whole mAb, Anti-CALCRL/CGRPR Antibody: Anti-CRLR/LMPHM8 therapeutic antibody
INN Name Erenumab
TargetCGRPR
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCLambda
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI Structure6umh:HL/6umi:HL/6umj:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesAmgen;Novartis
Conditions ApprovedMigraine
Conditions Activena
Conditions DiscontinuedHot flushes
Development TechAbgenix XenoMouse